Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $527,000 in Omnicell, Inc. $OMCL

Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,630 shares of the company’s stock, valued at approximately $527,000.

Other large investors also recently modified their holdings of the company. Dana Investment Advisors Inc. acquired a new stake in Omnicell in the fourth quarter worth $3,445,000. Assenagon Asset Management S.A. grew its holdings in Omnicell by 83.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after purchasing an additional 117,556 shares during the period. Peregrine Capital Management LLC acquired a new stake in Omnicell in the fourth quarter worth $4,804,000. Dynamic Technology Lab Private Ltd grew its holdings in Omnicell by 345.9% in the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after purchasing an additional 24,738 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Omnicell by 71.1% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock worth $6,343,000 after purchasing an additional 58,193 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on OMCL. Craig Hallum restated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a report on Wednesday, April 29th. KeyCorp raised their price target on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Benchmark restated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Finally, Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $59.86.

Omnicell Stock Up 4.1%

Omnicell stock opened at $43.60 on Friday. Omnicell, Inc. has a fifty-two week low of $26.84 and a fifty-two week high of $55.00. The stock has a market cap of $1.98 billion, a PE ratio of 99.09, a price-to-earnings-growth ratio of 1.08 and a beta of 0.97. The firm’s 50-day simple moving average is $39.70 and its 200 day simple moving average is $41.31. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts predict that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Insider Activity

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 15,520 shares of company stock worth $607,610. Insiders own 2.92% of the company’s stock.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.